Maxim Group initiated coverage on BioHarvest Sciences with a new price target
$BHST
Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/5/2025 | $15.00 | Buy | Craig Hallum |
| 12/18/2024 | $12.00 | Buy | Maxim Group |
Rehovot, Israel--(Newsfile Corp. - September 22, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, which fortifies the Company's balance sheet with an additional $10.9 Million in gross proceeds and a concurrent $3.8 Million reduction in total debt.The following are the transactions which were executed subsequent to the Company's published Q2 2025 Financial Statements:Successfully raised $5.8 Million in incremental cash through the exercising of 898,277 w
Exosomes Produced in the Liquid Media of the BioHarvest Unique Large-Scale Bioreactors Add Potential New Revenue Stream from Products and CDMO OpportunitiesRehovot, Israel--(Newsfile Corp. - September 10, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it has successfully produced, at scale, plant-based exosomes in its bioreactor media, marking a significant advancement in the Company's proprietary Botanical Synthesis platform and in its ability to generate new revenue streams.Exosomes are nano-sized extracellular vesicles naturally secreted by plant cel
Rehovot, Israel--(Newsfile Corp. - September 2, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will host a Virtual Investor Webinar on Wednesday, September 10, 2025 at 1:00 p.m. Eastern time.CEO Ilan Sobel will host the virtual investor webinar to provide a corporate update on new capability-building initiatives, the Company's 'Big Bets' for 2H 2025, and will conclude with a question-and-answer session from dial-in participants. To attend, please reference the access information below: Virtual Investor WebinarDate: Wednesday, September 10, 20
424B7 - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
424B7 - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
Craig Hallum initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $15.00
Maxim Group initiated coverage of BioHarvest Sciences with a rating of Buy and set a new price target of $12.00
Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the BoardVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ:BHST) (CSE:BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately."We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division
Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product SalesRehovot, Israel--(Newsfile Corp. - August 11, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025.Second Quarter 2025 HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the second quarter of 2025 increased 41% year-over-year to $8.5 million, in line with management guidance, with gross margins of 60% expanding by 800 basis points y
Rehovot, Israel--(Newsfile Corp. - August 4, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the second quarter ended June 30, 2025 before market open on Monday, August 11, 2025.Management will host an investor conference call and webcast at 8:00 a.m. Eastern time on Monday, August 11, 2025 to discuss the Company's second quarter 2025 financial results, provide a corporate update, and conclude with a question-and-answer session from telephone participants. To participate, please use the following information:Second Q
First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceRehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March 31, 2025.First Quarter & Subsequent 2025 Operational HighlightsAll figures stated in this news release are in U.S. dollars unless stated otherwise. Total revenues for the first quarter of 2025 increased 47% year-over-year to $7.9 million, exceeding management guidance, with gross margins expanding by 227 basis points to 58.